Biochem/physiol Actions

Hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) has a role in non-alcoholic fatty liver disease (NAFLD) and it has been shown to be downregulated in hepatocellular carcinoma. HSD17B13 modulates lipid biosynthesis.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

General description

Hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) is part of the short-chain dehydrogenase/reductase family. The gene encoding this lipid droplet-associated protein is localized on human chromosome 4q22.1.

Immunogen

Fusion protein corresponding to a region derived from internal residues of human hydroxysteroid (17-beta) dehydrogenase 13

Physical form

Rabbit IgG in pH7.3 PBS, 0.05% NaN₃, 50% Glycerol.

Specificity

The antibody detects endogenous levels of total HSD17B13 protein.